Octreotide Acetate
Total Payments
$168,651
Transactions
8
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $96,767 | 4 | 0 |
| 2019 | $71,868 | 3 | 0 |
| 2017 | $16.03 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $168,635 | 7 | 100.0% |
| Food and Beverage | $16.03 | 1 | 0.0% |
Payments by Type
Research
$168,635
7 transactions
General
$16.03
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OCTR-1-19114 | Mylan Pharmaceuticals Inc. | $168,635 | 0 |
Top Doctors Receiving Payments for Octreotide Acetate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $168,635 | 7 |
| , M.D | Dermatology | Henderson, NV | $16.03 | 1 |
Ad
Manufacturing Companies
- Mylan Pharmaceuticals Inc. $168,651
Product Information
- Type Drug
- Total Payments $168,651
- Total Doctors 1
- Transactions 8
About Octreotide Acetate
Octreotide Acetate is a drug associated with $168,651 in payments to 1 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Pharmaceuticals Inc..
Payment data is available from 2017 to 2020. In 2020, $96,767 was paid across 4 transactions to 0 doctors.
The most common payment nature for Octreotide Acetate is "Unspecified" ($168,635, 100.0% of total).
Octreotide Acetate is associated with 1 research study, including "OCTR-1-19114" ($168,635).